TFPI2 promotes NK cell–mediated glioblastoma killing through adhesion and checkpoint control
Proceedings of the National Academy of Sciences · 23.06.2026 · 123 (25)
DOI: 10.1073/pnas.2529973123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.06.2026. Verfasst von Dongpeng Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin 300072, China. Hauptthemen laut MEDLINE: Killer Cells, Natural, Glioblastoma, Glycoproteins, Brain Neoplasms. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune-mediated killing triggers dynamic transcriptional adaptations in tumor cells that can reciprocally regulate the cytolytic process. Unraveling such feedback mechanisms is crucial for advancing cancer immunotherapy. Here, we identified tissue factor pathway inhibitor 2 (TFPI2) as a central node in natural killer (NK)–glioblastoma cross talk. Using transcriptomic and functional approaches, we demonstrated that NK cell attack induces TFPI2 expression in glioblastoma cells via IL1β- and TNFα-driven activation of NFκB signaling. TFPI2 not only restrains tumor proliferation by suppressing the POU2F2–CCND1 axis but also enhances NK cytotoxicity through two complementary mechanisms: It supports optimal ICAM1 expression to promote NK–tumor adhesion, and it selectively represses the immune checkpoint molecule SIGLEC15, restoring NK cell effector function. In vivo, loss of TFPI2 accelerates glioblastoma progression and abrogates the efficacy of adoptive NK cell therapy in a context-dependent manner; the functionality is likely restricted to tumors retaining the capacity for TFPI2 induction upon inflammatory stimuli. Our findings identified the TFPI2–ICAM1 and TFPI2–SIGLEC15 axes as conditional regulators of immune–tumor adhesion and checkpoint control, supporting TFPI2 as a candidate therapeutic target for a subset of glioblastomas amenable to inflammatory reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin 300072, China.
- State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin 300072, China.
- The State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing 210042, China.
- Tianjin University and Health-Biotech United Group Joint Laboratory of Innovative Drug Development and Translational Medicine, Tianjin University, Tianjin 300072, China.
- Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, China.
- Tianjin Key Laboratory of Cerebral Blood Flow Reconstruction and Head and Neck Tumor New Technology Translation, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Neurosurgical Institut…
ORCID-Profile: Fengqi Li, Jingyue Yang, Budong Chen, Shupeng Sun, Zichuan Liu, Xin Mu
Zitieren
APA
Zheng, D., Li, F., Zhang, Z., Dong, Y., Zhang, X., Li, X., Yang, J., Peng, S., Chen, B., Sun, S., Liu, Z., & Mu, X. (2026). TFPI2 promotes NK cell–mediated glioblastoma killing through adhesion and checkpoint control. Proceedings of the National Academy of Sciences, 123(25). https://doi.org/10.1073/pnas.2529973123
Vancouver
Zheng D, Li F, Zhang Z, Dong Y, Zhang X, Li X, et al. TFPI2 promotes NK cell–mediated glioblastoma killing through adhesion and checkpoint control. Proceedings of the National Academy of Sciences. 2026;123(25). doi:10.1073/pnas.2529973123
BibTeX
@article{Zheng2026,
author = {Zheng, Dongpeng and Li, Fengqi and Zhang, Zhuang and Dong, Yunyi and Zhang, Xuebin and Li, Xueren and Yang, Jingyue and Peng, Shouchun and Chen, Budong and Sun, Shupeng and Liu, Zichuan and Mu, Xin},
title = {TFPI2 promotes NK cell–mediated glioblastoma killing through adhesion and checkpoint control},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {25},
doi = {10.1073/pnas.2529973123}
}
EUVIMED